Business Wire

CEOs of Largest Global Companies Positive and Pushing for Growth, Arthur D. Little Research Finds

21.2.2023 15:00:00 EET | Business Wire | Press release

Share

Arthur D. Little (ADL) today launched its 2023 CEO Insights Study, highlighting that the leaders of the world’s biggest companies are confident despite the current turmoil. Sixty-three percent expect a stable or positive economic outlook over the next three to five years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005413/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arthur D. Little CEO Insights 2023: Turning turmoil to advantage: How CEOs are navigating change to drive growth (Graphic: Business Wire)

Despite the downturn, CEOs are focused on growth – half say they will enter new geographies, and 30 percent expect to grow faster than the wider market. Even cautious CEOs expect to increase growth investments, with 40 percent spending more and 55 percent keeping expenditure constant. At the same time, leading CEOs are becoming truly ambidextrous, combining this innovation with laser focus on cost optimization.

CEO confidence in the future can be attributed to the lessons learned from the pandemic, which forced many businesses to transform their operations. Ninety-one percent of CEOs understand that developing fit-for-purpose capabilities that drive optimization and efficiency, as well as innovation and growth, are now mission critical. This is likely to lead to a different capability mix enabling companies to unleash their full potential moving forward.

However, there are differing pictures between regions. Thirty-eight percent of European CEOs in the top five economies of France, Germany, Italy, Spain, and the UK expect to see a positive economic outlook over the next three to five years, against just 25 percent of those in North America and 10 percent in Asia.

CEOs see technology innovation as the most critical factor to company growth, and are moving beyond digitalization to embrace technologies such as AI, robotics and automation. They are also looking forward – 60 percent want to explore new technologies, and 27 percent believe the metaverse and virtual reality will impact their business.

Hearteningly, 80 percent of CEOs believe focusing on environmental, social and governance (ESG) delivers competitive advantage, rather than simply being a compliance cost. In fact, 41 percent of CEOs rank it as a higher priority than all other initiatives.

Francesco Marsella, Managing Partner and Global Practice Leader, Strategy & Organization at Arthur D. Little, comments: “In a downturn, conventional business wisdom is to cut costs and focus on survival. Despite current challenges and many dark macroeconomic predictions for 2023, most CEOs we spoke to are optimistic for the future, working with passion, entrepreneurship, and creativity to manage performance today while building for the future. They see opportunity in adversity, looking beyond the current crisis to embrace a more positive future for their companies and wider society.”

The Arthur D. Little 2023 CEO Insights Study interviewed nearly 250 global CEOs leading companies with a turnover of more than USD 1 billion. Fifty-five percent of the sample employed over 10,000 people. Study respondents are split between key industries and geographies to give unrivaled insight into the minds of those running the world’s biggest organizations.

The full report, including recommendations from ADL, can be downloaded from https://tinyurl.com/ypc7yvx4.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information from:

Cate Bonthuys / Sue Glanville
Catalyst Comms
+44 7715 817589
info@catalystcomms.co.uk

For further information, please visit www.adlittle.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye